43.44 USD
+0.01 (+0.02%)
43.05 USD
-0.39 (-0.9%)
EXEL gets a fundamental rating of 8 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. EXEL has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. An interesting combination arises when we look at growth and value: EXEL is growing strongly while it also seems undervalued. These ratings could make EXEL a good candidate for value and growth and quality investing.
1. Profitability
1.1 Basic Checks
In the past year EXEL was profitable.
In the past year EXEL had a positive cash flow from operations.
EXEL had positive earnings in each of the past 5 years.
Each year in the past 5 years EXEL had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 24.01%, EXEL belongs to the top of the industry, outperforming 97.38% of the companies in the same industry.
EXEL has a Return On Equity of 31.37%. This is amongst the best in the industry. EXEL outperforms 97.57% of its industry peers.
EXEL's Return On Invested Capital of 26.31% is amongst the best of the industry. EXEL outperforms 98.69% of its industry peers.
EXEL had an Average Return On Invested Capital over the past 3 years of 10.78%. This is significantly below the industry average of 18.60%.
The last Return On Invested Capital (26.31%) for EXEL is above the 3 year average (10.78%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.01% | ||
| ROE | 31.37% | ||
| ROIC | 26.31% |
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
1.3 Margins
EXEL's Profit Margin of 29.63% is amongst the best of the industry. EXEL outperforms 96.07% of its industry peers.
EXEL's Profit Margin has declined in the last couple of years.
EXEL has a Operating Margin of 35.85%. This is amongst the best in the industry. EXEL outperforms 97.57% of its industry peers.
In the last couple of years the Operating Margin of EXEL has declined.
EXEL's Gross Margin of 96.63% is amongst the best of the industry. EXEL outperforms 96.25% of its industry peers.
In the last couple of years the Gross Margin of EXEL has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 35.85% | ||
| PM (TTM) | 29.63% | ||
| GM | 96.63% |
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so EXEL is creating value.
The number of shares outstanding for EXEL has been reduced compared to 1 year ago.
The number of shares outstanding for EXEL has been reduced compared to 5 years ago.
EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
EXEL has an Altman-Z score of 12.69. This indicates that EXEL is financially healthy and has little risk of bankruptcy at the moment.
EXEL's Altman-Z score of 12.69 is amongst the best of the industry. EXEL outperforms 85.77% of its industry peers.
EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 12.69 |
ROIC/WACC3.01
WACC8.73%
2.3 Liquidity
A Current Ratio of 3.75 indicates that EXEL has no problem at all paying its short term obligations.
EXEL has a Current ratio (3.75) which is in line with its industry peers.
EXEL has a Quick Ratio of 3.68. This indicates that EXEL is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 3.68, EXEL perfoms like the industry average, outperforming 47.57% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.75 | ||
| Quick Ratio | 3.68 |
3. Growth
3.1 Past
EXEL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.51%, which is quite impressive.
Measured over the past years, EXEL shows a quite strong growth in Earnings Per Share. The EPS has been growing by 12.65% on average per year.
Looking at the last year, EXEL shows a quite strong growth in Revenue. The Revenue has grown by 9.93% in the last year.
The Revenue has been growing by 17.51% on average over the past years. This is quite good.
EPS 1Y (TTM)44.51%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%72.5%
Revenue 1Y (TTM)9.93%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%10.79%
3.2 Future
EXEL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.76% yearly.
Based on estimates for the next years, EXEL will show a quite strong growth in Revenue. The Revenue will grow by 9.99% on average per year.
EPS Next Y29.57%
EPS Next 2Y25.25%
EPS Next 3Y26.07%
EPS Next 5Y25.76%
Revenue Next Year7.2%
Revenue Next 2Y9.82%
Revenue Next 3Y11.52%
Revenue Next 5Y9.99%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 18.33, which indicates a rather expensive current valuation of EXEL.
EXEL's Price/Earnings ratio is rather cheap when compared to the industry. EXEL is cheaper than 94.19% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.15, EXEL is valued a bit cheaper.
A Price/Forward Earnings ratio of 14.97 indicates a correct valuation of EXEL.
96.44% of the companies in the same industry are more expensive than EXEL, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of EXEL to the average of the S&P500 Index (36.22), we can say EXEL is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.33 | ||
| Fwd PE | 14.97 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of EXEL indicates a rather cheap valuation: EXEL is cheaper than 96.07% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, EXEL is valued cheaper than 96.07% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.94 | ||
| EV/EBITDA | 11.82 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of EXEL may justify a higher PE ratio.
A more expensive valuation may be justified as EXEL's earnings are expected to grow with 26.07% in the coming years.
PEG (NY)0.62
PEG (5Y)1.45
EPS Next 2Y25.25%
EPS Next 3Y26.07%
5. Dividend
5.1 Amount
EXEL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
43.44
+0.01 (+0.02%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners96.89%
Inst Owner Change-0.36%
Ins Owners2.23%
Ins Owner Change-3.14%
Market Cap11.65B
Revenue(TTM)2.29B
Net Income(TTM)677.90M
Analysts78.46
Price Target45.9 (5.66%)
Short Float %7.68%
Short Ratio7.44
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.63%
Min EPS beat(2)9.27%
Max EPS beat(2)13.99%
EPS beat(4)4
Avg EPS beat(4)20.73%
Min EPS beat(4)9.27%
Max EPS beat(4)49.01%
EPS beat(8)7
Avg EPS beat(8)31.52%
EPS beat(12)9
Avg EPS beat(12)17.76%
EPS beat(16)13
Avg EPS beat(16)41.2%
Revenue beat(2)0
Avg Revenue beat(2)-1.87%
Min Revenue beat(2)-3.02%
Max Revenue beat(2)-0.72%
Revenue beat(4)1
Avg Revenue beat(4)1.05%
Min Revenue beat(4)-3.02%
Max Revenue beat(4)9.31%
Revenue beat(8)3
Avg Revenue beat(8)4.36%
Revenue beat(12)4
Avg Revenue beat(12)2.52%
Revenue beat(16)7
Avg Revenue beat(16)3.42%
PT rev (1m)1.54%
PT rev (3m)0%
EPS NQ rev (1m)16.08%
EPS NQ rev (3m)20.6%
EPS NY rev (1m)-0.02%
EPS NY rev (3m)1.42%
Revenue NQ rev (1m)0.11%
Revenue NQ rev (3m)-0.01%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.08%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.33 | ||
| Fwd PE | 14.97 | ||
| P/S | 5.09 | ||
| P/FCF | 14.94 | ||
| P/OCF | 14.72 | ||
| P/B | 5.39 | ||
| P/tB | 5.55 | ||
| EV/EBITDA | 11.82 |
EPS(TTM)2.37
EY5.46%
EPS(NY)2.9
Fwd EY6.68%
FCF(TTM)2.91
FCFY6.7%
OCF(TTM)2.95
OCFY6.79%
SpS8.53
BVpS8.06
TBVpS7.82
PEG (NY)0.62
PEG (5Y)1.45
Graham Number20.73
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.01% | ||
| ROE | 31.37% | ||
| ROCE | 33.48% | ||
| ROIC | 26.31% | ||
| ROICexc | 44.11% | ||
| ROICexgc | 46.12% | ||
| OM | 35.85% | ||
| PM (TTM) | 29.63% | ||
| GM | 96.63% | ||
| FCFM | 34.08% |
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
ROICexc(3y)19.16%
ROICexc(5y)19.43%
ROICexgc(3y)20.04%
ROICexgc(5y)20.66%
ROCE(3y)13.72%
ROCE(5y)11.89%
ROICexgc growth 3Y9.55%
ROICexgc growth 5Y2.44%
ROICexc growth 3Y10.88%
ROICexc growth 5Y3.03%
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
F-Score8
Asset Turnover0.81
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 37.81% | ||
| Cap/Sales | 0.49% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 93.06% | ||
| Profit Quality | 115.03% | ||
| Current Ratio | 3.75 | ||
| Quick Ratio | 3.68 | ||
| Altman-Z | 12.69 |
F-Score8
WACC8.73%
ROIC/WACC3.01
Cap/Depr(3y)129.54%
Cap/Depr(5y)238.73%
Cap/Sales(3y)1.75%
Cap/Sales(5y)2.56%
Profit Quality(3y)151.16%
Profit Quality(5y)151.8%
High Growth Momentum
Growth
EPS 1Y (TTM)44.51%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%72.5%
EPS Next Y29.57%
EPS Next 2Y25.25%
EPS Next 3Y26.07%
EPS Next 5Y25.76%
Revenue 1Y (TTM)9.93%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%10.79%
Revenue Next Year7.2%
Revenue Next 2Y9.82%
Revenue Next 3Y11.52%
Revenue Next 5Y9.99%
EBIT growth 1Y34.85%
EBIT growth 3Y34.01%
EBIT growth 5Y13.3%
EBIT Next Year41.83%
EBIT Next 3Y24.19%
EBIT Next 5Y1.16%
FCF growth 1Y112.18%
FCF growth 3Y25.89%
FCF growth 5Y5.48%
OCF growth 1Y99.5%
OCF growth 3Y20.43%
OCF growth 5Y5.84%
EXELIXIS INC / EXEL FAQ
What is the fundamental rating for EXEL stock?
ChartMill assigns a fundamental rating of 8 / 10 to EXEL.
What is the valuation status for EXEL stock?
ChartMill assigns a valuation rating of 8 / 10 to EXELIXIS INC (EXEL). This can be considered as Undervalued.
What is the profitability of EXEL stock?
EXELIXIS INC (EXEL) has a profitability rating of 8 / 10.
What are the PE and PB ratios of EXELIXIS INC (EXEL) stock?
The Price/Earnings (PE) ratio for EXELIXIS INC (EXEL) is 18.33 and the Price/Book (PB) ratio is 5.39.